Open AccessAssociation of fecal and serum microRNA profiles with gastrointestinal cancer and chronic inflammatory enteropathy in dogs
Author(s) -
Lyngby Janne G.,
Gòdia Marta,
Brogaard Louise,
Kristensen Annemarie T.,
Fredholm Merete,
Skancke Ellen,
Morris Joanna,
Dupont Nana,
Salavati Schmitz Silke,
Argyle David,
Sánchez Armand,
Bjørnvad Charlotte R.,
GraarupHansen Kasper,
Spohr Anette,
Cirera Susanna,
Nielsen Lise N.
Publication year - 2022
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/jvim.16530
Subject(s) - medicine , feces , gastroenterology , enteropathy , area under the curve , microrna , colorectal cancer , area under curve , real time polymerase chain reaction , immunology , cancer , disease , biology , pharmacokinetics , paleontology , biochemistry , gene
Background Reliable biomarkers to differentiate gastrointestinal cancer (GIC) from chronic inflammatory enteropathy (CIE) in dogs are needed. Fecal and serum microRNAs (miRNAs) have been proposed as diagnostic and prognostic markers of GI disease in humans and dogs. Hypothesis/Objectives Dogs with GIC have fecal and serum miRNA profiles that differ from those of dogs with CIE. Aims: (a) identify miRNAs that differentiate GIC from CIE, (b) use high‐throughput reverse transcription quantitative real‐time PCR (RT‐qPCR) to establish fecal and serum miRNA panels to distinguish GIC from CIE in dogs. Animals Twenty‐four dogs with GIC, 10 dogs with CIE, and 10 healthy dogs, all client‐owned. Methods An international multicenter observational prospective case‐control study. Small RNA sequencing was used to identify fecal and serum miRNAs, and RT‐qPCR was used to establish fecal and serum miRNA panels with the potential to distinguish GIC from CIE. Results The best diagnostic performance for distinguishing GIC from CIE was fecal miR‐451 (AUC: 0.955, sensitivity: 86.4%, specificity: 100%), miR‐223 (AUC: 0.918, sensitivity: 90.9%, specificity: 80%), and miR‐27a (AUC: 0.868, sensitivity: 81.8%, specificity: 90%) and serum miR‐20b (AUC: 0.905, sensitivity: 90.5%, specificity: 90%), miR‐148a‐3p (AUC: 0.924, sensitivity: 85.7%, specificity: 90%), and miR‐652 (AUC: 0.943, sensitivity: 90.5%, specificity: 90%). Slightly improved diagnostic performance was achieved when combining fecal miR‐451 and miR‐223 (AUC: 0.973, sensitivity: 95.5%, specificity: 90%). Conclusions and Clinical Importance When used as part of a diagnostic RT‐qPCR panel, the abovementioned miRNAs have the potential to function as noninvasive biomarkers for the differentiation of GIC and CIE in dogs.